3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
1
Status
Terminated
5
Completed
1
Sponsor Class
INDUSTRY
5
Study Type
Interventional
5
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
2
Breast
1
Conditions
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
1
Non-squamous Non-small Cell Lung Cancer
1
Non-small Cell Lung Cancer Metastatic
1
Breast Cancer Metastatic
1
Adenocarcinoma Gastric
1
Interventions
pembrolizumab
111
Carboplatin
45
Nivolumab
41
Paclitaxel
34
Cyclophosphamide
32
Cisplatin
32
Gemcitabine
30
atezolizumab
27
Specimen Handling
25
venetoclax
24
Magnetic Resonance Spectroscopy
24
Pemetrexed
23
fludarabine
22
Biopsy
22
Radiotherapy
21
Ipilimumab
21
Docetaxel
21
Bevacizumab
21
Azacitidine
21
Radiosurgery
18
durvalumab
17
Fluorouracil
17
Dexamethasone
17
Cetuximab
16
fludarabine phosphate
14
Trastuzumab
14
Leucovorin
13
Cytarabine
13
tislelizumab
12
olaparib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
5 trials
Recent
Start date
Enrollment
Terminated
×
tusamitamab ravtansine
×
1 year
×
Clear all
NCT04154956
2026-05-18
CARMEN-LC03
Sanofi
Phase 3
Terminated
389 enrolled
16 charts
NCT04524689
2025-10-29
CARMEN-LC05
Sanofi
Phase 2
Terminated
57 enrolled
26 charts
NCT04659603
2025-10-01
CARMEN-BT01
Sanofi
Phase 2
Terminated
50 enrolled
20 charts
NCT05245071
2025-08-29
CARMEN-LC06
Sanofi
Phase 2
Terminated
22 enrolled
11 charts
NCT05071053
2025-08-22
CARMEN-GC01
Sanofi
Phase 2
Terminated
35 enrolled
14 charts